Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of autologous LCAT gene-transduced preadipocyte therapy in familial LCAT deficiency
jRCT2033240371Recruiting
- Sponsor
- CellGenTech
- Start
- Oct 2024
- Countries
- 1
01
Overview
Open-label, single-arm trial in Familial lecithin:cholesterol acyltransferase deficiency (FLD), sponsored by CellGenTech. Primary endpoints: RCR emergence after administration of the clinical trial product, Tumorigenesis at the administration site and 2 more. Started Oct 2024; status: recruiting.
02
Conditions
Familial lecithin:cholesterol acyltransferase deficiency (FLD)
Beyond the preview
Go deeper on jRCT2033240371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033240371.